
Number of publications published per year by Friedman, Scott L.. (Source : PubMed)

Distribution of publications types for Friedman, Scott L.. (Source : PubMed)
(a publication can be of different types, so total may exceed publications count)


Tumor suppressor activity of KLF6 mediated by downregulation of the PTTG1 oncogene.
FEBS Lett.
2010;584;5
Downregulation of hepatic stellate cell activation by retinol and palmitate mediated by adipose differentiation-related protein (ADRP).
J. Cell. Physiol.
2010;223;3

Kupffer cell activation by ambient air particulate matter exposure may exacerbate non-alcoholic fatty liver disease.
J Immunotoxicol
2009;6;4

Therapeutic targeting of the PDGF and TGF-beta-signaling pathways in hepatic stellate cells by PTK787/ZK22258.
Lab. Invest.
2009;89;10

Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo.
J. Hepatol.
2009;51;4
Multiple variants in toll-like receptor 4 gene modulate risk of liver fibrosis in Caucasians with chronic hepatitis C infection.
J. Hepatol.
2009;51;4
Kupffer cell activation by ambient air particulate matter exposure may exacerbate non-alcoholic fatty liver disease.
J Immunotoxicol
2009

Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma.
Cancer Res.
2009;69;18

Antifibrotic effects of CXCL9 and its receptor CXCR3 in livers of mice and humans.
Gastroenterology
2009;137;1
Resveratrol amplifies profibrogenic effects of free fatty acids on human hepatic stellate cells.
Hepatol. Res.
2009;39;6
[ See timeline ] [ See all publications ]
means that Friedman, Scott L. has 67 papers cited a least 67 times - methodology
Division of Liver Diseases, Department of Medicine, Mount Sinai School of Medicine, New York, NY 10029, USA.
Due mainly to homonyms, errors are possible and if you detect "false positives" or "false negatives" don't be too frustrated and please contact the webmaster.